Cargando…

Weight Gain: A Possible Side Effect of All Antiretrovirals

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taramasso, Lucia, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Passerini, Simone, Madeddu, Giordano, Martinelli, Canio Vito, De Socio, Giuseppe Vittorio, Squillace, Nicola, Rusconi, Stefano, Bonfanti, Paolo, Di Biagio, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727459/ https://www.ncbi.nlm.nih.gov/pubmed/29255735 http://dx.doi.org/10.1093/ofid/ofx239

Ejemplares similares

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
por: Maggi, Paolo, et al.
Publicado: (2022)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study
por: De Socio, Giuseppe Vittorio, et al.
Publicado: (2020)

Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
por: De Vito, Andrea, et al.
Publicado: (2023)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project
por: Squillace, Nicola, et al.
Publicado: (2017)

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2019)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
por: Taramasso, Lucia, et al.
Publicado: (2022)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
por: Bonfanti, Paolo, et al.
Publicado: (2020)

Reversibility of Central Nervous System Adverse Events in Course of Art
por: Taramasso, Lucia, et al.
Publicado: (2022)

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
por: Bagella, Paola, et al.
Publicado: (2018)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study
por: Maggi, Paolo, et al.
Publicado: (2019)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda
por: Guaraldi, Giovanni, et al.
Publicado: (2023)

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort
por: Nicolini, Laura Ambra, et al.
Publicado: (2023)

Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use
por: Maggi, P., et al.
Publicado: (2019)

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
por: Madeddu, G, et al.
Publicado: (2010)

Cardiovascular risk and dyslipidemia among persons living with HIV: a review
por: Maggi, Paolo, et al.
Publicado: (2017)

Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study
por: Muscatello, Antonio, et al.
Publicado: (2020)

Injectable Antiretroviral Drugs: Back to the Future
por: Berruti, Marco, et al.
Publicado: (2021)

HIV and SARS-CoV-2 Co-Infection: What are the Risks?
por: Squillace, Nicola, et al.
Publicado: (2021)

Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study
por: Vadini, Francesco, et al.
Publicado: (2019)

Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

107. Impact of Switching to an Antiretroviral Regimen Containing Tenofovir Alafenamide on Weight Gain and Development of Metabolic Side Effects
por: Darnell, Julia, et al.
Publicado: (2020)

Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study
por: De Socio, Giuseppe Vittorio, et al.
Publicado: (2017)

The Adiponectin Paradox for All-Cause and Cardiovascular Mortality
por: Menzaghi, Claudia, et al.
Publicado: (2018)

951. Weight Gain Associated With Antiretroviral Therapy
por: Patel, Yesha, et al.
Publicado: (2020)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy
por: Taramasso, Lucia, et al.
Publicado: (2018)

Erratum. The Adiponectin Paradox for All-Cause and Cardiovascular Mortality. Diabetes 2018;67:12–22
por: Menzaghi, Claudia, et al.
Publicado: (2018)

SARS-CoV-2 Vaccination Among Incarcerated People: A Barrier to Overcome
por: Fiore, Vito, et al.
Publicado: (2021)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_83k3b5gh82vpfroblg0lvtqind